Polynitroxyl-albumin (PNA) enhances myocardial infarction therapeutic effect of tempol in rat hearts subjected to regional ischemia-reperfusion.
Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl, TPL), a low molecular weight stable nitroxyl radical (nitroxide), has been demonstrated in many in vitro and in vivo models to have protective effects against oxidative stress. The beneficial effect of TPL, however, is limited because of its short life-time in tissues. We have previously shown that polynitroxylated macromolecules such as polynitroxyl-human serum albumin (PNA) enable maintaining a sustained concentration of TPL for longer periods in tissues. PNA itself has previously been shown to inhibit ischemia-reperfusion (I/R) injury in the gut and to potentiate the activity of TPL. The aim of the present study was (i) to select an optimum formulation of PNA + TPL for therapeutic applications using in vivo EPR spectroscopy and (ii) to evaluate the efficacy of the PNA + TPL formulation in preventing I/R injury to heart, in an in vivo rat model. Rats were subjected to 45 min occlusion of the left anterior descending (LAD) coronary artery followed by 120 min reperfusion. PNA (100 mg/ml) + TPL (10 mg/ml), human serum albumin (HSA, 100 mg/ml) + TPL (10 mg/ml), or saline were injected 5 min before ischemia (3 ml/kg BW, i.v.) and 5 min before reperfusion (3 ml/kg BW, i.v.), followed by a 4 ml/kg BW infusion over 2 h reperfusion. Myocardial risk and infarct regions were then estimated. The results showed that the infarct volume, expressed as a percentage of the risk region, in the group treated with PNA + TPL was 39.7 +/- 3.1%, which was significantly smaller than for the saline (51.3 +/- 3.5%) or HSA + TPL (48.4 +/- 1.4%) groups. The results demonstrate that the PNA + TPL combination is very effective in reducing myocardial ischemia-reperfusion injury.
Li
Haiquan
H
Division of Cardiology and the EPR Center, Department of Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD 21224, USA.
Ma
Li
L
Hsia
Carleton J C
CJ
Zweier
Jay L
JL
Kuppusamy
Periannan
P
D000418:Albumins / Q000627:therapeutic use*; D000818:Animals; D003497:Cyclic N-Oxides / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004578:Electron Spin Resonance Spectroscopy; D005260:Female; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000209:etiology; D015428:Myocardial Reperfusion Injury / Q000150:complications / Q000517:prevention & control*; D009589:Nitrogen Oxides / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013113:Spin Labels
D000418:Albumins; D003497:Cyclic N-Oxides; D009589:Nitrogen Oxides; D013113:Spin Labels; C117059:polynitroxyl-albumin; C001803:tempol